Correlation Between Foghorn Therapeutics and SAB Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Foghorn Therapeutics and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Foghorn Therapeutics and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Foghorn Therapeutics and SAB Biotherapeutics, you can compare the effects of market volatilities on Foghorn Therapeutics and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Foghorn Therapeutics with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Foghorn Therapeutics and SAB Biotherapeutics.
Diversification Opportunities for Foghorn Therapeutics and SAB Biotherapeutics
-0.18 | Correlation Coefficient |
Good diversification
The 3 months correlation between Foghorn and SAB is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Foghorn Therapeutics and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Foghorn Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Foghorn Therapeutics are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Foghorn Therapeutics i.e., Foghorn Therapeutics and SAB Biotherapeutics go up and down completely randomly.
Pair Corralation between Foghorn Therapeutics and SAB Biotherapeutics
Given the investment horizon of 90 days Foghorn Therapeutics is expected to under-perform the SAB Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Foghorn Therapeutics is 5.79 times less risky than SAB Biotherapeutics. The stock trades about -0.03 of its potential returns per unit of risk. The SAB Biotherapeutics is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest 5.00 in SAB Biotherapeutics on August 30, 2024 and sell it today you would earn a total of 1.83 from holding SAB Biotherapeutics or generate 36.6% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 86.96% |
| Values | Daily Returns |
Foghorn Therapeutics vs. SAB Biotherapeutics
Performance |
| Timeline |
| Foghorn Therapeutics |
| SAB Biotherapeutics |
Foghorn Therapeutics and SAB Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Foghorn Therapeutics and SAB Biotherapeutics
The main advantage of trading using opposite Foghorn Therapeutics and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Foghorn Therapeutics position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.| Foghorn Therapeutics vs. Ikena Oncology | Foghorn Therapeutics vs. Eliem Therapeutics | Foghorn Therapeutics vs. HCW Biologics | Foghorn Therapeutics vs. RenovoRx |
| SAB Biotherapeutics vs. SAB Biotherapeutics | SAB Biotherapeutics vs. Jasper Therapeutics | SAB Biotherapeutics vs. NRx Pharmaceuticals | SAB Biotherapeutics vs. Surrozen Warrant |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |